Inclisiran in Dyslipidemia with High Residual Platelet Reactivity
Kapsultanova D. Zhangelova S. Nurmukhammad F. Makasheva Z. Sakhov O. Galkina T. Rustamova F. Akhmentayeva D. Aubakirova B.
January 2026Multidisciplinary Digital Publishing Institute (MDPI)
Diseases
2026#14Issue 1
Background: High residual platelet reactivity (HRPR) and persistent dyslipidemia remain important unmet needs in cardiovascular risk management, particularly in patients undergoing coronary revascularization. Despite intensive lipid-lowering and antiplatelet therapy, a substantial proportion of patients fail to reach recommended low-density lipoprotein cholesterol (LDL-C) targets or exhibit inadequate platelet inhibition. Inclisiran, a PCSK9-targeting small interfering RNA, represents an emerging approach for long-term LDL-C reduction. Methods: A narrative review of the literature published between 2009 and 2025 was performed using PubMed, Scopus, Web of Science, and MEDLINE. Studies evaluating the addition of inclisiran to standard lipid-lowering therapy in patients with dyslipidemia and HRPR, assessed using the VerifyNow assay, were included. Illustrative clinical cases from Kazakhstan were analyzed to demonstrate real-world changes in LDL-C levels and platelet reactivity following insufficient response to conventional treatment. The review had a descriptive design. Results: Available evidence indicates that a significant proportion of high- and very-high-risk patients do not achieve LDL-C targets or are unable to tolerate high-intensity statin therapy. Inclisiran consistently induces sustained reductions in LDL-C and circulating PCSK9 levels. Emerging data suggest a potential indirect modulation of platelet reactivity associated with intensive lipid lowering. In patients at extreme cardiovascular risk—including those after coronary artery bypass grafting (CABG) and with long-standing multivessel coronary artery disease—inclisiran therapy was associated with marked LDL-C reduction and a trend toward normalization of platelet reactivity. Conclusions: Assessment of platelet function using the VerifyNow assay may improve identification of residual thrombotic risk in patients with advanced atherosclerotic disease. Inclisiran appears to be a promising adjunctive therapy for dyslipidemic patients with persistently elevated cardiovascular risk and HRPR despite standard treatment. Further prospective studies are warranted to clarify the relationship between intensive LDL-C lowering, platelet reactivity, and clinical outcomes, and to optimize integrated lipid-lowering and antiplatelet strategies.
familial hypercholesterolemia , high residual platelet reactivity , inclisiran , LDL cholesterol , platelet function testing , revascularization
Text of the article Перейти на текст статьи
Faculty of Postgraduate Education, Asfendiyarov Kazakh National Medical University, Almaty, 050012, Kazakhstan
Faculty of Postgraduate Medical Education, Hodja Ahmed Yasawi International Kazakh-Turkish University, Turkestan, 161200, Kazakhstan
Department of Cardiology, City Cardiology Center, Almaty, 050000, Kazakhstan
Department of Cardiology, Medical Center «AMAST», Astana, 010000, Kazakhstan
Faculty of Postgraduate Education
Faculty of Postgraduate Medical Education
Department of Cardiology
Department of Cardiology
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026